Furthermore, trials with anti-BCMA CAR-T cells in earlier stages of the disease are ongoing and CAR-T cells targeting other multiple myeloma antigens such as CD38, CD138, and SLAMF7 are also being explored. Here, TNFRSF17 is linked to plasma cell myeloma.